GLS

Glenmark Life Sciences Share Price

₹1,013.30 -3.85 (-0.38%)

21 Dec, 2024 18:02

SIP TrendupStart SIP in GLS

Start SIP

Performance

  • Low
  • ₹1,006
  • High
  • ₹1,030
  • 52 Week Low
  • ₹627
  • 52 Week High
  • ₹1,335
  • Open Price₹1,017
  • Previous Close₹1,017
  • Volume90,190

Investment Returns

  • Over 1 Month -6.43%
  • Over 3 Month -12.03%
  • Over 6 Month + 20.68%
  • Over 1 Year + 59.98%
SIP Lightning

Smart Investing Starts Here Start SIP with Glenmark Life Sciences for Steady Growth!

Invest Now

Glenmark Life Sciences Fundamentals Fundamentals refer to the financial data that companies report on a quarterly or annual basis.

  • P/E Ratio
  • 29.3
  • PEG Ratio
  • -1.8
  • Market Cap Cr
  • 12,416
  • P/B Ratio
  • 5.3
  • Average True Range
  • 39.65
  • EPS
  • 34.56
  • Dividend Yield
  • 0
  • MACD Signal
  • -13.39
  • RSI
  • 40.88
  • MFI
  • 56.64

Glenmark Life Sciences Financials

Glenmark Life Sciences Technicals

EMA & SMA

Current Price
₹1,013.30
-3.85 (-0.38%)
pointer
  • stock-down_img
  • Bullish Moving Average 3
  • stock-up_img
  • Bearish Moving Average 13
  • 20 Day
  • ₹1,044.73
  • 50 Day
  • ₹1,062.11
  • 100 Day
  • ₹1,041.18
  • 200 Day
  • ₹964.51

Resistance and Support

1016.27 Pivot Speed
  • R3 1,051.53
  • R2 1,040.77
  • R1 1,027.03
  • S1 1,002.53
  • S2 991.77
  • S3 978.03

What's your outlook on Glenmark Life Sciences?

You can only vote for once

Ratings

Master Rating

EPS Strenth

Price Strength

Buyer Demand

Group Rank

Glenmark Life Sciences develops and manufactures high-quality Active Pharmaceutical Ingredients (APIs), supplying over 130 molecules to more than 700 global pharmaceutical companies. With world-class manufacturing and research capabilities, GLS focuses on operational excellence, regulatory compliance, and innovation.

Glenmark Life Sciences has an operating revenue of Rs. 2,204.90 Cr. on a trailing 12-month basis. An annual revenue growth of 5% is not great, Pre-tax margin of 28% is great, ROE of 20% is exceptional. The company is debt free and has a strong balance sheet enabling it to report stable earnings growth across business cycles. The stock from a technical standpoint is trading below to its 50DMA and around 7% up from its 200DMA. It needs to take out the 50DMA levels and stay above it to make any further meaningful move. It is currently FORMING a base in its weekly chart and is trading around 23% away from the crucial pivot point. From an O'Neil Methodology perspective, the stock has an EPS Rank of 43 which is a POOR score indicating inconsistency in earnings, a RS Rating of 57 which is POOR indicating the underperformance as compared to other stocks, Buyer Demand at A- which is evident from recent demand for the stock, Group Rank of 56 indicates it belongs to a fair industry group of Medical-Ethical Drugs and a Master Score of C is fair but needs to improve. Institutional holding has gone up in the last reported quarter is a positive sign. Overall, the stock has poor technical strength and poor fundamentals, there are superior stocks in the current market environment.

Disclaimer: This stock analysis report is algorithmically generated for informational purposes only and should not be considered as a buy or sell recommendation.

View More

Glenmark Life Sciences Corporate Actions - Bonus, Splits, Dividends

Date Purpose Remarks
2024-10-24 Quarterly Results
2024-07-25 Quarterly Results
2024-04-25 Audited Results
2024-01-23 Quarterly Results
2023-10-20 Quarterly Results
Date Purpose Remarks
2023-10-17 INTERIM Rs.22.50 per share(1125%)Interim Dividend
2023-03-24 INTERIM Rs.21.00 per share(1050%)Interim Dividend
2021-11-23 INTERIM Rs.10.50 per share(525%)Interim Dividend

Glenmark Life Sciences F&O

Glenmark Life Sciences Shareholding Pattern

75%
2.82%
0.08%
7.85%
0%
10.63%
3.62%

About Glenmark Life Sciences

  • NSE Symbol
  • GLS
  • BSE Symbol
  • 543322
  • Managing Director & CEO
  • Dr. Yasir Rawjee
  • ISIN
  • INE03Q201024

Similar Stocks to Glenmark Life Sciences

Glenmark Life Sciences FAQs

Glenmark Life Sciences share price is ₹1,013 As on 21 December, 2024 | 17:48

The Market Cap of Glenmark Life Sciences is ₹12415.8 Cr As on 21 December, 2024 | 17:48

The P/E ratio of Glenmark Life Sciences is 29.3 As on 21 December, 2024 | 17:48

The PB ratio of Glenmark Life Sciences is 5.3 As on 21 December, 2024 | 17:48

Open Free Demat Account

Be a part of 5paisa community - The first listed discount broker of India.

+91

By proceeding, you agree to all T&C*

footer_form

Disclaimer: Investment in securities market are subject to market risks, read all the related documents carefully before investing. For detailed disclaimer please Click here.

Q2FY23